Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia

Tremblay, Gabriel; Dolph, Mike; Bhor, Menaka; Said, Qayyim; Elliott, Brian; Briggs, Andrew; (2018) Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia. CLINICOECONOMICS AND OUTCOMES RESEARCH, 10. pp. 705-713. ISSN 1178-6981 DOI: https://doi.org/10.2147/CEOR.S177324

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.2147/CEOR.S177324

Abstract

Share

Download

Filename: Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia.pdf

Licence: Creative Commons: Attribution-Noncommercial 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar